Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants With Idiopathic Pulmonary Fibrosis (IPF) (ARGiNAUT)

NCT07652658 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07652658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07652658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants With Idiopathic Pulmonary Fibrosis (IPF) (ARGiNAUT)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Recruiting
Start date
June 11, 2026
Completion date
September 14, 2028
Enrollment
359 (estimated)
Sites
195

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis (ipf)